Evidence for a dominant negative disease mechanism in cap myopathy due to TPM3.

Abstract : We report a third patient with typical cap myopathy due to a heterozygous TPM3 mutation, confirming the importance of this causal association. The p.R168C TPM3 mutation we identified has been reported in two previous patients. The histological changes associated with this mutation vary widely from typical cap myopathy with near complete type 1 predominance (two patients), to typical congenital fibre-type disproportion without protein inclusions (one patient). We performed 2D-gel electrophoresis using muscle biopsies from two patients with the p.R168C mutation and show that mutant protein accounts for around 50% of alpha-tropomyosin(slow) in sarcomeres, consistent with a dominant negative mechanism of disease pathogenesis.
Type de document :
Article dans une revue
Neuromuscul Disord, 2010, 20 (7), pp.464-6. 〈10.1016/j.nmd.2010.05.012〉
Liste complète des métadonnées

Littérature citée [13 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00589053
Contributeur : Nathalie Roux-Buisson <>
Soumis le : mercredi 13 juillet 2011 - 13:13:41
Dernière modification le : jeudi 1 février 2018 - 01:12:04

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

U836 | UGA

Citation

Leigh Waddell, Michaela Kreissl, Andrew Kornberg, Paul Kennedy, Catriona Mclean, et al.. Evidence for a dominant negative disease mechanism in cap myopathy due to TPM3.. Neuromuscul Disord, 2010, 20 (7), pp.464-6. 〈10.1016/j.nmd.2010.05.012〉. 〈inserm-00589053〉

Partager

Métriques

Consultations de la notice

168